BioSpace News Archive

Kronos Bio, Inc., dedicated to targeting oncogenic transcription factors and associated transcriptional regulatory networks, today announced the appointment of Jennifer Nicholson, M.H.A., to the newly created position of Vice President, Regulatory Affairs. Ms. Nicholson joins the company with nearly 20 years of experience in regulatory affairs, with a focus on oncology across all stages of develop

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that David Fox has been appointed to Gamida Cell’s board of directors as an independent member. Mr. Fox brings significant leadership, company-building and business development experience to Gamida Cell’s board of directors as the company advances its clinical development candid

Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for transfusion. These data are consistent with prior INTERCEPT studies showing complete inactivation, to below the limit of detection, of other coronaviruses associated with severe pulmonary disease: MERS-CoV 1,2 (2018, 2019) a

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX ), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program. Dry Eye Disease (DED) – ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product line development that will

Data Published in eBioMedicine Validates Novel Scientific Approach That Disarms Bacterial Defenses to Treat or Prevent Life-threatening Infections Approach effectively degrades bacterial protective shields to enable immune or antibiotic intervention COLUMBUS, Ohio--( BUSINESS WIRE )-- Clarametyx Biosciences Inc ., (“Clarametyx”) a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent in

Initiation of pivotal PURSUIT trial is targeted for Q4 2020 following pending results from Companys SUI feasibility study, which is evaluating a new sham treatment tip PURSUIT clearance and pending results from the SUI feasibility study are significant milestones in Companys pursuit of a stress urinary incontinence indication in the U.S.

Kenergy Scientific Inc. is pleased to announce it has executed a Share Exchange agreement with “KNSC” and Florida based MedSmart Group, Inc. KNSC has acquired all of the issued and outstanding shares of MedSmart Group Inc. a Florida based medical wellness and antiaging centers focused on Men’s health.

StemSation International, Inc. (OTC PINK:STSN) - a pioneer in the emerging category of dietary supplements called Stem Cell Nutrition, announces it has filed a Statement of Use on four separate trademarks on which the US Patent & Trademark Office has granted a Notice of Allowance . StemSation, through its wholly-owned subsidiary, StemSation IP Holding LLC, plans to build a valuable portfolio of intellectual property, to include patents, tra

International Foundation for Gastrointestinal Disorders (IFFGD) recognizes three young investigators for their contributions to the advancement of science for chronic GI disorders

Nucleai (www.Nucleaimd.com), an Israeli start-up providing an artificial intelligence-powered precision oncology platform for research and treatment decisions and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, manufacturing and digital health investment, announced today the Series-A initial closing of $6.5M